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The Simplified Psoriasis Index (SPI): A Practical Tool
for Assessing Psoriasis
Leena Chularojanamontri1,2, Christopher E.M. Griffiths1 and Robert J.G. Chalmers1
The Simplified Psoriasis Index (SPI) is a summary measure of psoriasis with separate components for current
severity (SPI-s), psychosocial impact (SPI-p), and past history and interventions (SPI-i). It derives from the Salford
Psoriasis Index but replaces Psoriasis Area and Severity Index (PASI) with a composite weighted severity score
designed to reflect the impact of psoriasis affecting functionally or psychosocially important body sites. Two
complementary versions are available, differing only in that current severity (SPI-s) is either professionally
(proSPI-s) or patient self-assessed (saSPI-s). This study examined the criterion and construct validity and response
distribution of proSPI-s, saSPI-s, and SPI-p in 100 patients with plaque psoriasis. A further 50 patients were
assessed for test–retest reliability of these three components. Interrater reliability of proSPI-s was assessed in
12 patients, each assessed by 12 assessors (144 assessments). There was close correlation between PASI and
proSPI-s (r¼ 0.91); SPI-p was closely correlated with the Dermatology Life Quality Index (r¼ 0.89). Strong intrarater
(proSPI-s, saSPI-s, SPI-p, and SPI-i) and interrater (proSPI-s) reliability was demonstrated (all intraclass correlation
coefficients 40.75). There were wide response distributions for all three components. We believe that both
professional (proSPI) and self-assessed (saSPI) versions can readily be introduced into routine clinical practice.
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INTRODUCTION
Psoriasis is a disease that can cause major distress through its
effects on physical and psychological functioning. To docu-
ment whether professional management of psoriasis is achiev-
ing its intended effects, it is essential to have reliable means of
recording severity, disease impact, and response to therapeutic
intervention. In recent years, two instruments, the Psoriasis
Area and Severity Index (PASI) and the Dermatology Life
Quality Index (DLQI), have been widely used in clinical trials
for these purposes. The DLQI is not psoriasis specific but has
gained wide acceptance for recording the psychosocial impact
of skin disease (Lewis and Finlay, 2004). On the other hand,
PASI has neither been clearly defined nor properly validated.
The definitions of its constituent components are open to
interpretation and the required estimation of percentage body
surface area (BSA) is notoriously inaccurate (Ramsay and
Lawrence, 1991). It requires cumbersome arithmetic, making
it awkward to use in an everyday clinical setting. Furthermore
it takes no account of psoriasis distribution, giving equal
weight to psoriasis wherever it is located (Feldman, 2004).
Its validity remains questionable whether as a global summary
score of psoriasis severity or as a tool to assist in therapeutic
decision-making for patients with psoriasis (Gourraud et al.,
2012).
Development and initial evaluation of the Simplified Psoriasis
Index (SPI)
The SPI is closely modeled on the Salford Psoriasis Index,
which was originally devised in the late 1990s and was
intended to provide a concise but holistic summary of psori-
asis severity (Kirby et al., 2000) for use in routine clinical
practice. Its three components included separate indicators of
current severity, psychosocial impact, and historical course.
These components each contribute towards the disease
burden of psoriasis but cannot be simply summated. The
first component was derived from PASI and reflected current
severity. The second component recorded the patient’s
assessment of psychosocial impact using a 0–10 visual analog
scale. The third component was designed to reflect the
historical ‘‘difficulty’’ of disease management by scoring for
disease duration and the number of interventions received.
The current severity and psychosocial impact components
of the Salford Psoriasis Index showed significant correlation
with PASI and DLQI, respectively (Kirby et al., 2000).
Although the conceptual basis of the Index was favorably
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received by commentators (Yosipovitch and Tang, 2002), the
need to derive current severity from PASI with all its
drawbacks and the complex rules for calculating the history
and interventions score hindered its widespread adoption.
However, a recent systematic review of psoriasis outcome
measures stated that the Salford Psoriasis Index had good
content validity and deserved more extensive study (Puzenat
et al., 2010).
The SPI contains a composite severity score (SPI-s), which
dispenses with the need for PASI or BSA scoring. This was
developed in an iterative process by clinical testing in a large
specialist psoriasis center before being presented for comment
to a group of world experts on psoriasis assessment at the
Outcome Measures in Psoriasis workshop (International Psor-
iasis Council, New York, 2006). The psoriasis extent score
is weighted to reflect functional or psychosocial impact, with
extra weight given to the scalp, face, hands, feet, and
anogenital skin (van de Kerkhof et al., 2006). The extent in
each of the 10 unequal areas is accorded a separate value
using a 3-point scale (absent or minimal (0), ‘‘noticeable’’
(0.5), or extensive (1); Figure 1). The presence of significant
nail disease can be captured in the extent scores for hands and
feet (Figure 1). Scoring of plaque severity is simplified by using
a single overall average, as early pilot studies had shown that
there was little to be gained by scoring each of the 10 areas
individually (n¼ 19, r¼ 0.95) (Chalmers et al., 2008). The
6-point average plaque severity score removes the need to
assess erythema, scale, and plaque thickness separately
(Figure 1). This score (max¼5) multiplied by the extent score
(max¼10) is used to derive SPI-s (max¼50).
The SPI converts the 10-cm visual analog psychosocial
impact score (SPI-p) to the nearest integer (range 0–10) and
simplifies the historical course and interventions score (SPI-i)
by grouping questions, with four about disease course and six
about previous interventions (Figure 2). Its composition is,
however, intended to be flexible to accommodate variations
in practice between centers and the introduction of new
therapeutic agents in the future.
SPI is available in two complementary versions intended for
use by health professionals (proSPI) and for self-assessment
by patients (saSPI): both are freely available online as
Supplementary Data. Apart from the simplification of the
language used, the two proformas are essentially the same,
but professionally scored and self-assessed severity (proSPI-s
and saSPI-s, respectively) may diverge.
The proSPI is recorded in the same way as its predecessor,
with a triplet representing current severity (proSPI-s, saSPI-s:
max¼ 50), psychosocial impact (SPI-p: max¼ 10), and
historical course and interventions (SPI-i: max¼10). Thus, a
man with obvious but not widespread moderately thick
psoriasis affecting 6 out of 10 body areas has a proSPI-s of 9
(extent 60.5¼3 multiplied by average plaque severity of 3;
Figure 1). If his psoriasis is now starting to respond to a
biological agent but is longstanding (over 20 years), and has
failed multiple interventions (phototherapy and three conven-
tional systemic agents), then his SPI-p may be only 3 but his
intervention score would be 7 (Figure 2), giving a proSPI score
of 9:3:7. On the other hand, a teenage girl with recent-onset
psoriasis limited to the occipital scalp and elbows but
causing her immense distress would have a low proSPI-s
but a high SPI-p, e.g., 2:10:0. The saSPI is recorded similarly,
the only difference being that current severity is self-assessed,
thus giving insight into the patient’s own perception of
severity.
The ease of use and utility of proSPI was examined in
a small study in 2008 where experienced and trainee
dermatologists working in a busy psoriasis center were
asked to score 54 randomly selected patients using proSPI.
Even trainees who had not previously encountered proSPI felt
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describes the current extent of psoriasis in each body area
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1 Scalp and hairline
Face, neck, and ears
Arms and armpits
Hands, fingers, and fingernails*
2
3
4
6
7
8
9
10
5
1
0 Essentially clear: with faint erythema or residual pigmentation only
Moderate: erythema and/or scale and/or skin thickening
Marked: erythema and/or scale and/or skin thickening
Intensely inflamed skin: with or without pustulation
Clear or just slight redness of staining
Mild redness or scaling with no more than slight thickening
Definite redness, scaling, or thickening
Moderately severe with obvious redness, scaling, or thickening
Very red and inflamed, very scaly, or very thick
Intensely inflamed skin with or without pustules (pus spots)
You may be given some photographic images to help you score your psoriasis.
Mild: erythema and/or scale with focal slight palpable thickening
Mild-to-moderate: erythema and/or scale with majority of affected
skin palpably thickened
2
3
4
5
1
0
2
3
4
5
Chest and abdomen (stomach)
Back and shoulders
Buttocks and thighs
Knees, lower legs, and ankles
Feet, toes, and toenails*
*PSORIASIS OF THE NAILS: even if the skin of the
hands or feet is unaffected you can score ± for severe
psoriasis of at least 2 and + for 6 or more finger- or
toenails
Genital area and/or around anus (back passage)
Obvious but still leaving plenty of normal skin (0.5)
Widespread and involving much of the affected area (1.0) §
Clear or minimal with no more than a few scattered thin plaques (0)
§ Please note that this is not the same as percentage body surface area (BSA)
involvement: the extent score takes into account how dispersed the plaques are
Clear or so minor that it does not bother me (0)
Obvious but still leaving plenty of normal skin (0.5)
Widespread and involving much of the affected area (1.0)
PART 1A (saSPI) For each of these 10 body areas please
circle one choice that best describes your psoriasis today
PART 1B (proSPI) Select the option that best describes the current average severity
of psoriasis. This should take into account all affected areas identified above, not just the
worst areas. Please refer to photographic severity key if available.
PART 1B (saSPI) Please circle whichever of these choices best describes the
overall state of your psoriasis today. Your score should reflect the average of all your
psoriasis, not just the worst areas.
±
±
±
±
±
±
±
±
±
±
±
±
Figure 1. Professional (proSPI) and self-assessment (saSPI) versions of current
severity score. SPI, Simplified Psoriasis Index.
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that it was easily understandable and not time consuming
to complete. The utility of saSPI was examined in two
pilot studies conducted at our center and at Baylor Psoriasis
Center, Dallas, Texas, USA. Over two-thirds of the 78
recruited patients were able to complete saSPI correctly.
A wide range of scores was utilized for each component
of proSPI and saSPI, suggesting that there was little
redundancy in any of its components (presented at Psoriasis
2010, Congress of the Psoriasis International Network:
Paris, 2010).
Objectives
The current studies were designed to investigate the validity
and reliability of proSPI and saSPI.
Criterion validity compares an instrument to a well-estab-
lished or gold standard metric. We wished to compare:
a. proSPI-s with PASI.
b. saSPI-s with PASI.
c. SPI-p with DLQI.
Construct validity measures the extent to which an instru-
ment relates to other relevant metrics. To examine this in
greater detail, we wished to investigate the relationships
between current severity and psychosocial impact scores:
d. proSPI-s, saSPI-s, and PASI versus DLQI.
e. proSPI-s, saSPI-s, and PASI versus SPI-p.
To confirm the findings from pilot studies (Chalmers et al.,
2008) that replacing individual plaque severity scores for each
of the 10 body areas by a single average plaque severity score
to compute current severity (plaque severity extent) would
not result in a significant loss of sensitivity of proSPI-s and
saSPI-s, we also wished to compare:
f. proSPI-s and saSPI-s as derived from (1) the product of
average plaque severity sum of body area extent scores
and (2) the sum of products of individual plaque severity
body area extent.
The criterion and construct validity of SPI-i were not
investigated, as there are no standard and relevant measure-
ments for assessing history and interventions received for
psoriasis.
Response distribution examines whether the entire range
of a scale is used. We wished to demonstrate:
g. wide response distributions (lack of redundancy) in each of
the three domains of proSPI and saSPI.
Test–retest reliability measures how consistent scores
remain across multiple administrations of an instrument.
We wished to confirm:
h. the test–retest reliability of proSPI-s and saSPI-s.
i. the test–retest reliability of SPI-p and SPI-i.
Interrater reliability is the degree to which multiple obser-
vers agree on the assignment of scales. (This is not relevant to
saSPI for which only the affected individual can determine
how to score his or her own psoriasis.) Therefore, we wished
to measure:
j. the interrater reliability of proSPI-s.
RESULTS
Most of the 150 patients (83%) had psoriasis for more than
10 years and had received multiple interventions in the past
(SPI-i data): their mean age was 47 years (SD 14.5) and 55%
were women. Seventy-four of the patients had been admitted
to hospital for psoriasis, and 72 had had erythrodermic or
generalized pustular psoriasis; 121 patients had received pho-
totherapy and 49 had received biological agents (SPI-i data).
Criterion validity and construct validity
Comparison of the two instruments with PASI and DLQI. The
relationships between proSPI-s, saSPI-s, SPI-p, PASI and DLQI are
shown in Table 1. There was close correlation between proSPI-s
and PASI (r¼ 0.91) (Figure 3a), and between SPI-p and DLQI
(r¼ 0.89). The correlation between saSPI-s and PASI was
less strong (r¼ 0.70) (Figure 3b); however, saSPI-s was more
closely correlated with SPI-p (r¼ 0.78) and DLQI (r¼ 0.82) than
were either PASI (PASI vs. SPI-p: r¼ 0.62; PASI vs. DLQI: r¼ 0.60)
or proSPI-s (proSPI-s vs. SPI-p: r¼ 0.60; proSPI-s vs. DLQI:
r¼ 0.59).
Evaluation of the effect on proSPI-s and saSPI-s of replacing
assessment of individual plaque scores for each body area by
assessment of a single overall average score. We found little
difference between scores derived by assessing each body area
separately and a single overall average score. The correlations
PART 3   Give one point for each true statement / for each therapy
received (whether currently or in the past). Point
SUM
About patient’s psoriasis
Patient has had psoriasis for more than 10 years
Patient has had psoriasis for more than 20 years (additional point)
Patient has had erythrodermic or generalized pustular psoriasis
Patient has been admitted to hospital for psoriasis
About patient’s treatment
History and interventions score: maximum 10 points
Patient has had at least one course of UV treatment or PUVA
Patient has been treated with methotrexate (now or in past)
Patient has been treated with acitretin or etretinate (now or  in past)
Patient has been treated with another systemic agent for psoriasis
(now or in past)
Patient has been treated with ciclosporin (now or in past)
Patient has been treated with a “biological” drug (now or in past)
Name of treatmet: ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ....
Biological drugs include Remicade/infliximab; Enbrel/etanercept;
Raptiva/efalizumab; Humira/adalimumab; Stelara/ustekinumab
Figure 2. Self-assessment (saSPI) version of historical course and
interventions score (SPI-i). PUVA, psoralen plus UVA; SPI, Simplified Psoriasis
Index; SPI-i, historical course and interventions component of SPI.
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between the proSPI-s and saSPI-s derived by assessing individual
plaque scores in 10 body areas and a composite average plaque
severity score were very close (proSPI-s: r¼ 0.91, saSPI-s:
r¼ 0.92).
Response distribution. There was little redundancy in any of the
three components, with a wide range of scores obtained
(Figure 4). A greater range of proSPI-s scores was obtained during
the interrater validation exercise, for which patients had been
specifically selected to demonstrate a wide range of disease
severity, than among patients attending routine outpatient clinic
appointments (Figure 4a). Patients tended to give themselves
higher scores than those given by the author LC (Figure 4a).
The full range of scores was utilized in the other two domains
(Figure 4b and c).
Test–retest reliability. The intraclass correlation coefficients
(ICCs) for proSPI-s and saSPI-s were 0.93 (95% confidence
interval (CI): 0.88–0.96) and 0.82 (95% CI: 0.70–0.89), respec-
tively. The ICCs for SPI-p and SPI-i were 0.75 (95% CI: 0.58–0.84)
and 0.95 (95% CI: 0.92–0.97), respectively. These ICCs indicate
strong reliability of each of the three components of SPI.
Interrater reliability. Table 2 demonstrates that PASI had strong
interrater reliability if undertaken by experienced psoriasis asses-
sors (ICC¼ 0.92), but this was not the case for inexperienced
assessors (ICC¼ 0.53). On the other hand, similar and strong
interrater reliability of proSPI-s was demonstrated for both
experienced and inexperienced assessors, only one of whom
(author RJGC) was familiar with proSPI (ICC¼ 0.80 and 0.82,
respectively).
DISCUSSION
Over the past half century, there have been enormous
changes in the way therapeutic interventions are evaluated
before being accepted into clinical practice. The wide-
spread adoption over this period of controlled clinical trial
methodology has necessitated the development of tools by
which alternative interventions can be compared. For many
interventions, such tools are straightforward (e.g., reduction in
death rates); however, in areas such as rheumatology and
dermatology, assessing benefit is not quite so straightforward.
In a study of randomized controlled psoriasis trials published
in major journals between 1977 and 2000, it was found that
44 different outcome measures were used in the 249 trials
identified (Naldi et al., 2003). PASI was, however, the most
popular, being used in one-third of the trials: its limitations
have already been discussed at the beginning of this paper.
In designing SPI, we aimed to avoid many of the unsatis-
factory features of PASI, which include:
(a) its component elements have never been formally
defined and are open to wide interpretation; in particular,
desquamation was never defined and has by custom been
taken to mean scale thickness rather than scale shedding.
(b) the assumption that a plaque of psoriasis is of equal
importance to the patient wherever it is located on the
body and that it is therefore valid and desirable to measure
the percentage BSA involvement irrespective of its
distribution.
(c) the requirement to estimate BSA, which is recognized to
be prone to large intra- and interrater variability.
(d) the fact that one or two small plaques of psoriasis (e.g., on
the elbow tips) must be given the same weight as extensive
small plaque or guttate psoriasis largely covering the upper
limbs but, when assessed accurately, frequently involving
o10% BSA.
(e) the pseudo-scientific precision and complex arithmetic
required to compute PASI with a consequent high risk of
error.
Thus, in SPI, the division of the body surface into 10
unequal areas (Figure 1) was intended to give extra promi-
nence to those parts of the body where psoriasis is more likely
to have an impact on self-esteem or normal functioning. The
restriction to just three choices for each area has simplified the
scoring of extent; furthermore, the extent score takes into
account dispersal as well as the proportion of skin affected by
psoriasis and is thus, we believe, more likely to represent
the impact of psoriasis than does BSA involvement alone.
The correlation between severity scores (proSPI-s, saSPI-s)
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Figure 3. Correlations between Simplified Psoriasis Index (SPI) and Psoriasis
Area and Severity Index (PASI) current severity assessments in 100 psoriasis
patients. (a) proSPI-s versus PASI and (b) saSPI-s versus PASI. proSPI-s, severity
component of professional Simplified Psoriasis Index; saSPI-s, severity
component of the self-assessment Simplified Psoriasis Index.
Table 1. The relationships between proSPI-s, saSPI-s,
SPI-p, PASI, and DLQI
Spearman rank
correlation coefficients proSPI-s saSPI-s PASI SPI-p DLQI
proSPI-s 0.70 0.91 0.60 0.59
saSPI-s 0.70 0.70 0.78 0.82
PASI 0.91 0.70 0.62 0.60
SPI-p 0.60 0.78 0.62 0.89
DLQI 0.59 0.82 0.60 0.89
Abbreviations: DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area
and Severity Index; proSPI-s, severity component of the professional
Simplified Psoriasis Index; saSPI-s, severity component of the self-assess-
ment Simplified Psoriasis Index; SPI-p, psychosocial impact score of the
Simplified Psoriasis Index.
Bold entries indicate the most important results as discussed in the text.
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obtained by assessing psoriasis severity separately for each of
the 10 areas and those from a single overall average score
(r¼0.91) was slightly less than that found in the pilot study
from St John’s Institute of Dermatology, London, UK (r¼ 0.95);
however, it was felt to be sufficiently close to justify continued
use of the much simpler, single overall average score to derive
proSPI-s and saSPI-s. The psychosocial impact and historical
course and interventions components add easily captured
extra information to give a far more informative score than
current severity alone. In designing SPI, we had to strike a
compromise between comprehensiveness and practicality: we
opted not to include separate components for symptoms (e.g.,
pruritus or joint pain) or for associated arthritis. On the other
hand, we feel strongly that regular self-assessment by patients
gives physicians valuable insight into their patients’ changing
views of their psoriasis and its impact.
The Lattice System Physician’s Global Assessment (LS-PGA)
integrates percentage BSA involvement (divided into six
ranges) and overall plaque quality into a composite severity
score similar to SPI-s. The LS-PGA showed a good correlation
with PASI and provided better intrarater and interrater relia-
bility than PASI (Langley and Ellis, 2004). This study
has shown that there is also a good correlation between
proSPI-s and PASI (Table 1). LS-PGA has the disadvantage
that it requires an estimate of percent BSA involvement,
which has been shown to be very difficult to score consistently
and accurately (Marks et al., 1989; Ramsay and Lawrence,
1991). We believe that the use of a three-point scale for
evaluating the extent of psoriasis in proSPI-s and saSPI-s is not
only more straightforward to use but, by moving from body
surface area involvement to an assessment of dispersal of
psoriasis, reflects better the patient’s perception of disease
extent.
The ICCs for interrater and intrarater variability that we
found in our studies compares favorably with those reported in
studies of LS-PGA and PASI (Puzenat et al., 2010). Our studies
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Figure 4. Response distributions for the various domains of proSPI and saSPI. (a) Current severity as assessed professionally (144 and 100 proSPI-s assessments
in two cohorts of 12 and 100 patients, respectively) and by patients (100 saSPI-s assessments); (b) SPI-p (n¼ 100); and (c) SPI-i (n¼ 100). proSPI-s, severity
component of professional Simplified Psoriasis Index; saSPI-s, severity component of the self-assessment Simplified Psoriasis Index; SPI-i, historical course
and interventions component of SPI; SPI-p, psychosocial impact score of the Simplified Psoriasis Index.
Table 2. ICCs for PASI and proSPI-s
Interrater reliability, ICCs (95% CI)
Clinical scales Six assessors (experienced in PASI,
five inexperienced in proSPI)
Six assessors (inexperienced in PASI,
inexperienced in proSPI)
Sum
(12 assessors)
PASI 0.92 (0.83–0.97) 0.53 (0.29–0.79) 0.73 (0.54–0.89)
proSPI-s 0.80 (0.63–0.93) 0.82 (0.66–0.93) 0.82 (0.68–0.93)
Abbreviations: CI, confidence interval; ICCs, intraclass correlation coefficients; PASI, Psoriasis Area and Severity Index; proSPI-s, severity component of
professional Simplified Psoriasis Index.
The six assessors included three dermatologists and three dermatology nurses.
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have also shown that there is strong interrater agreement
reliability even when SPI-s is used by inexperienced assessors.
We have more recently developed a photographic image key
giving several examples of each of the six severity grades to
assist both professionals and patients in scoring average
plaque severity. This may contribute to even greater
consistency.
The Copenhagen Psoriasis Severity Index has some of the
same advantages as SPI, namely, the removal of the need to
estimate the percent BSA and extra weighting for functionally
or psychosocially important anatomical sites (Berth-Jones
et al., 2008). However, the need for separate assessment of
erythema, plaque thickness, and scaling for each of the 10
different sites makes it significantly more cumbersome to use.
Neither LS-PGA nor Copenhagen Psoriasis Severity Index
attempt to capture information on the psychosocial impact of
psoriasis. Two instruments that do are the National Psoriasis
Foundation-Psoriasis Score (NPF-PS) and the Beer Sheva
Psoriasis Severity Score (BPSS). The NPF-PS and BPSS amal-
gamate physician and patient assessments and a patient
questionnaire on specific signs and symptoms into a single
score (Carlin et al., 2003; Gottlieb et al., 2003; Cohen et al.,
2005, 2008); we would question the validity of this and firmly
believe that the different components should be kept separate.
Furthermore, neither instrument has as yet been properly
validated.
The close correlation between SPI-p and DLQI in our study
confirms that SPI-p is a good instrument for assessing the
psychological impact of psoriasis. It is interesting to note that
there was closer correlation between saSPI-s and the two
psychological impact scores (SPI-p and DLQI) than between
the latter and the two professionally assessed severity scores
(proSPI-s and PASI) (Table 1). Thus, the saSPI-s would appear
to incorporate an element of psychosocial impact, with
patients who are more troubled by their psoriasis tending to
grade their psoriasis more severely.
The Salford Psoriasis Index contains a summary score for
historical course and severity (Kirby et al. 2000): changes in
therapeutic practice since its publication have necessitated the
modification of SPI-i. We believe that SPI-i provides a valuable
extra dimension that is not captured by SPI-s or SPI-p: it is
sufficiently flexible to accommodate further change as
necessary in the future.
We believe that proSPI and saSPI are complementary and
that the latter can provide a valuable record of patients’ own
perceptions of their disease. Our own experience has demon-
strated that both can readily be introduced into routine clinical
practice for monitoring patient response to treatment and
disease activity over time. Further studies are currently
examining the suitability of proSPI and saSPI for use in clinical
trials by formally assessing their interpretability and respon-
siveness to change. The acceptability of SPI is being assessed
in other countries and languages.
MATERIALS AND METHODS
The COSMIN checklist was used to evaluate the methodological
quality of this study (Mokkink et al., 2010). A total of 150 individuals
randomly selected from adult patients attending a National Health
Service tertiary referral psoriasis center in the United Kingdom were
invited to participate and gave their consent to do so. proSPI and
saSPI were each available as a single double-sided English language
printed proforma. With the exception of interrater reliability testing,
all scores and responses were completed either by the participant or
by author LC, who had been trained in the use of PASI and SPI by
author RJGC.
Data and responses for saSPI, PASI, and DLQI were collected for all
participants. proSPI was completed in a subset of 100; in 55 of these,
individual plaque severity scores for each body area and an average
plaque severity score were recorded both by LC and by the patient.
The study involved the use of questionnaires and assessment forms
already in routine clinical use in our department. Institutional
approval was thus not required. The study was conducted according
to the Declaration of Helsinki Principles.
Spearman’s correlation coefficient using a two-tailed test was
computed for each comparison, with ranges of 40.8, 0.5–0.8, and
o0.5 accepted as indicators of good, average, and poor correlation,
respectively (Gourraud et al., 2012). Statistical Package for the Social
Sciences (SPSS, Chicago, IL) version 17 was used for analysis.
Test–retest reliability was assessed in 50 individuals who were
recruited at random from patients required to reattend 1 week after
initial attendance. The 1-week interval was selected as a good
compromise to avoid simple repetition of the previous score, but
before there was likely to have been a significant change in disease
severity. As recording of SPI forms part of the standard assessment in
our center, potential subjects were requested to complete saSPI and to
have proSPI-s recorded by LC but were not told about the study at this
stage, to guard against them recording their own responses. At their
review attendance, the rationale for the repeat testing was explained
and those patients who consented were asked to complete saSPI
again. LC then repeated proSPI-s without reference to her previous
score or to the patient-assessed scores. ICC was used at the end of the
study for examining the test–retest reliability of the proSPI-s, saSPI-s,
SPI-p, and SPI-i.
Interrater reliability testing was assessed in a single session in which
12 patients (nine men and three women) with a wide range of
psoriasis severity participated. Six dermatologists and six dermatology
nurses, three of whom in each group were familiar with PASI scoring,
were each given 15min to complete proSPI and PASI assessments for
each patient. Other than a basic instruction sheet for each instrument,
no prior training was given. Only one of the assessors (RC) was
familiar with SPI. The sequence (PASI or proSPI first) was randomized
for each of the 144 pairs of assessments. Results were analyzed using
ICC: ICC values of 0–0.40, 0.40–0.75, and 0.75–1.0 indicate poor,
average, and strong agreement, respectively (Gourraud et al., 2012).
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